Antibody response in immunocompromised patients after the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: A randomised controlled trial.Speich, B., et al.
Clinical Infectious Diseases 2022 [record in progress].
This study aimed to evaluate the antibody reponse to SARS-CoV-2 vaccines, BNT162b and mRNA-1273, in immunocompromised patients.
Participants were randomly assigned to receive mRNA-1273 or BNT162b2.
430 HIV (PLWH) or solid organ transplant recipients (SOTR; i.e. lung and kidney).
The primary outcome was antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain 8 weeks following second vaccination.
This RCT compared the antibody response to the Pfizer (BNT162b2) and Moderna (mRNA-1273) COVID vaccines in immunosuppressed patients (HIV, lung and kidney transplant). The Moderna vaccine was found to be non-inferior to the Pfizer vaccine in these populations. Of note – a high proportion of solid-organ transplant recipients in both groups had no antibody response. Whilst the study was not blinded, this is likely to have limited impact on the objective outcomes reported. The low response to both vaccines in the SOTR cohort is of note, and future studies should compare the response to booster vaccines of both types.
ClinicalTrials.gov - NCT04805125